- Home
- QNCX vs CNTX Comparison
QNCX vs CNTX Comparison
Compare QNCX & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNCX
- CNTX
- Stock Information
- Founded
- QNCX 2012
- CNTX 2015
- Country
- QNCX United States
- CNTX United States
- Employees
- QNCX N/A
- CNTX N/A
- Industry
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- QNCX Health Care
- CNTX Health Care
- Exchange
- QNCX Nasdaq
- CNTX Nasdaq
- Market Cap
- QNCX 85.9M
- CNTX 75.6M
- IPO Year
- QNCX 2019
- CNTX 2021
- Fundamental
- Price
- QNCX $1.60
- CNTX $0.81
- Analyst Decision
- QNCX Strong Buy
- CNTX Strong Buy
- Analyst Count
- QNCX 6
- CNTX 5
- Target Price
- QNCX $8.00
- CNTX $5.25
- AVG Volume (30 Days)
- QNCX 124.9K
- CNTX 151.3K
- Earning Date
- QNCX 11-12-2025
- CNTX 11-05-2025
- Dividend Yield
- QNCX N/A
- CNTX N/A
- EPS Growth
- QNCX N/A
- CNTX N/A
- EPS
- QNCX N/A
- CNTX N/A
- Revenue
- QNCX N/A
- CNTX N/A
- Revenue This Year
- QNCX N/A
- CNTX N/A
- Revenue Next Year
- QNCX N/A
- CNTX N/A
- P/E Ratio
- QNCX N/A
- CNTX N/A
- Revenue Growth
- QNCX N/A
- CNTX N/A
- 52 Week Low
- QNCX $0.69
- CNTX $0.49
- 52 Week High
- QNCX $2.45
- CNTX $2.59
- Technical
- Relative Strength Index (RSI)
- QNCX 47.89
- CNTX 48.26
- Support Level
- QNCX $1.56
- CNTX $0.81
- Resistance Level
- QNCX $1.65
- CNTX $0.89
- Average True Range (ATR)
- QNCX 0.07
- CNTX 0.05
- MACD
- QNCX 0.00
- CNTX -0.01
- Stochastic Oscillator
- QNCX 64.65
- CNTX 1.82
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.